Form 4: Alto Neuroscience CEO Gifts 400,000 Shares for Estate Planning

Alto Neuroscience's President and CEO, Amit Etkin, gifted 400,000 shares of common stock to an irrevocable trust for estate planning purposes.

Summary

• Amit Etkin, President and CEO, Director, and 10% owner of Alto Neuroscience, Inc. (ANRO), reported a change in beneficial ownership.
• On May 14, 2026, Etkin disposed of 400,000 shares of common stock.
• The transaction was a bona fide gift for no consideration ($0 price) for estate planning purposes.
• The shares were transferred to the Bard on Haven Trust, an irrevocable trust, for the benefit of his spouse and children.
• Following the transaction, Etkin beneficially owns 833,949 shares directly.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged sale or disposition.
• Etkin does not retain voting, dispositive, or pecuniary interest over the securities held by the trust.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine insider transaction for estate planning, which is generally not a negative signal. The use of a 10b5-1 plan adds transparency to the transaction.

Positives

• The transaction was a gift for estate planning, not a sale for personal liquidity, which is generally viewed more favorably by investors.
• The use of a Rule 10b5-1 plan indicates pre-planning and adherence to insider trading regulations, enhancing transparency.

Negatives

• A significant reduction in direct beneficial ownership by a key executive, even if for estate planning, could be interpreted by some as a slight decrease in direct alignment with public shareholders, although the shares remain within the family's broader beneficial ownership.

Future Outlook

No future outlook or guidance is provided in this Form 4 filing.

Industry Context

StockSavvy.ai notes that insider gifts for estate planning are common and generally viewed as less impactful than open-market sales, especially when executed under a 10b5-1 plan, which demonstrates compliance and pre-planning in the biotechnology and pharmaceutical industry.

Comparison to Industry Standards

• This Form 4 represents a standard insider transaction filing for a gift, consistent with common estate planning practices observed across various industries, including biotechnology. There are no specific comparable companies, projects, or results to assess against this type of disclosure.

Related Party Transactions

• The transfer of 400,000 shares to the Bard on Haven Trust, an irrevocable trust for the benefit of the reporting person's spouse and children, constitutes a related party transaction for estate planning purposes.

Stakeholder Impact

• Shareholders: A slight reduction in direct insider ownership by the CEO, but the shares remain within the family's broader beneficial interest. This type of transaction typically has minimal direct impact on share price unless misinterpreted as a lack of confidence.
• Management: The CEO has executed a personal estate planning strategy, which is a common practice for high-net-worth individuals.

Key Dates

Recommendation

This Form 4 reports a routine insider gift for estate planning purposes, not a sale for liquidity. Such transactions, especially when executed under a 10b5-1 plan, are generally not indicative of a change in management's confidence in the company's future prospects and do not warrant a change in investment recommendation based solely on this filing.

Keywords

Alto Neuroscience, ANRO, Amit Etkin, Form 4, Insider Transaction, Stock Gift, Estate Planning, Beneficial Ownership, CEO, Director, 10b5-1 Plan